Holen Sie sich die Stockscreener-App
4.41
3.76%
0.16
Handel nachbörslich:
4.37
-0.04
-0.91%
Schlusskurs vom Vortag:
$4.25
Offen:
$4.3
24-Stunden-Volumen:
407.81K
Relative Volume:
0.14
Marktkapitalisierung:
$55.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.54M
KGV:
-2.8452
EPS:
-1.55
Netto-Cashflow:
$-18.30M
1W Leistung:
+6.27%
1M Leistung:
-11.98%
6M Leistung:
+687.50%
1J Leistung:
+1,769%
1-Tages-Spanne:
$4.23
$4.42
1-Wochen-Bereich:
$3.97
$4.43
52-Wochen-Spanne:
$0.2461
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Firmenname
Unicycive Therapeutics Inc
Sektor
Branche
Telefon
650-384-0642
Adresse
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Vergleichen Sie UNCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.41 | 51.20M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | Guggenheim | Buy |
| 2024-04-04 | Eingeleitet | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc.UNCY - FinancialContent
Why Unicycive Therapeutics Inc. is moving today2025 Major Catalysts & Free Growth Oriented Trading Recommendations - Newser
Will Unicycive Therapeutics Inc. bounce back from current supportM&A Rumor & High Conviction Trade Alerts - Newser
Momentum divergence signals in Unicycive Therapeutics Inc. chartFree Verified Signal From Chart Patterns - Newser
Real time pattern detection on Unicycive Therapeutics Inc. stockLong Term Equity Screener with Safety Metrics - Newser
Is it time to cut losses on Unicycive Therapeutics Inc.Machine Learning Intraday Signal Forecast - Newser
Does Unicycive Therapeutics Inc. fit your quant trading modelEntry Timing with Downside Risk Analysis - Newser
Does Unicycive Therapeutics Inc. qualify in momentum factor screeningFree High Growth Low Risk Stock Selection - Newser
How to integrate Unicycive Therapeutics Inc. into portfolio analysis toolsFree Scalable Portfolio Growth Suggestions - Newser
Is a relief rally coming for Unicycive Therapeutics Inc. holdersBreakout Watcher with Entry and Exit Alerts - Newser
Technical signs of recovery in Unicycive Therapeutics Inc.Free Real Profit Trade Plan Suggestions - Newser
Will breakout in Unicycive Therapeutics Inc. lead to full recoveryStock Price Prediction Using AI Tools - Newser
Is Unicycive Therapeutics Inc. impacted by rising ratesFree Screener for Explosive Stocks - thegnnews.com
Using Python tools to backtest Unicycive Therapeutics Inc. strategiesFree Exit Ready Momentum Stock Watchlist - Newser
Why Unicycive Therapeutics Inc. stock attracts strong analyst attentionAnnual Market Behavior and Sector Summary - Newser
What high frequency data says about Unicycive Therapeutics Inc.Swing Entry Risk Mitigation with Chart Analysis - Newser
Institutional scanner results for Unicycive Therapeutics Inc.Free Stable Entry High Return Opportunities - Newser
Real time social sentiment graph for Unicycive Therapeutics Inc.Long-Term Stock Growth Forecast Insights - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect - ACCESS Newswire
Unicycive Therapeutics: Pomerantz LLP Investigating Securities Fraud Claims - AInvest
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
What drives Unicycive Therapeutics Inc. stock priceNavigate the market with precision tools - Jammu Links News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics Inc. Stock Analysis and ForecastBuild wealth faster with expert stock picks - Jammu Links News
What are Unicycive Therapeutics Inc. company’s key revenue driversFind the best stocks for sustainable growth - Jammu Links News
Technical analysis overview for Unicycive Therapeutics Inc. stockPrice Action Summary and Entry Strategy Guide - Newser
What makes Unicycive Therapeutics Inc. stock price move sharplyOutstanding trading profits - Jammu Links News
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 1,211.2% in July - Defense World
Is Unicycive Therapeutics Inc. a growth stock or a value stockFree Popular Stock Recommendations - Jammu Links News
Does Unicycive Therapeutics Inc. stock perform well during market downturnsExceptional financial outcomes - Jammu Links News
What are the technical indicators suggesting about Unicycive Therapeutics Inc.Jaw-dropping returns - Jammu Links News
How many analysts rate Unicycive Therapeutics Inc. as a “Buy”High-profit capital plays - Jammu Links News
When is Unicycive Therapeutics Inc. stock expected to show significant growthExceptional gains - Jammu Links News
Unicycive Therapeutics Inc. stock trendline breakdownWeekly Stock Picks with Trend Confidence - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Finanzdaten der Unicycive Therapeutics Inc-Aktie (UNCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):